Nerviano Medical Sciences S.r.l. Announces a Poster Presentation on NMS-03602173 at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
NERVIANO, 25 October 2022 – Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that preclinical data from the Company’s asset NMS-03602173 will be reported in a poster presentation by Dr. Paola Magnaghi at the upcoming EORTC-NCI-AACR Symposium […]
NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR
Nerviano Medical Sciences S.r.l. Announces Data on NMS-01940153E selected for Oral Presentation at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics NERVIANO, 18 October 2022 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that […]
Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
NERVIANO, 21 September 2022 Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 […]
PROTAC (PROteolysis TArgeting Chimera)
Mirizzi D Chimica e Farmaceutica (2022), 6, 39-43
Molecular glues: un diverso approccio in drug discovery
Picconi P Chimica e Farmaceutica (2022), 6, 34-38
Prossimità chimicamente indotta
Mirizzi D Chimica e Farmaceutica (2022), 5, 48-52
Use of acridinium-based photocatalyst in the Giese-type coupling of arylboronic acids with electron poor olefins
Caldarelli M, Loriz L, Piazza L, Caputo G, DeAmici M, Papeo G Tetrahedron Letters (2022) 103, 153978
Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids
Casuscelli F, Ardini E, Avanzi N, Badari A, Casale E, Disingrini T, Donati D, Ermoli A, Felder E, Galvani A, Isacchi A, Menichincheri M, Montemartini M, Orrenius C, Piutti C, Salom B, Papeo G Chirality (2022), 34(11), 1437-1452
BL-01, an Fc-bearing, tetravalent CD20 × CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo
Interdonato A, Choblet S, Sana M, Valgardsdottir R, Cribioli S, Alzani R, Roth M, Duonor-Cerutti M, Golay J Cytotherapy (2022), 24(2), 161-171
First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours
Schöffski P, Awada A, de la Bigne A, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S Eur J Cancer (2022), 169 (135-145)
